These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 34281743)
1. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction. Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743 [TBL] [Abstract][Full Text] [Related]
2. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680 [TBL] [Abstract][Full Text] [Related]
3. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN; Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506 [TBL] [Abstract][Full Text] [Related]
4. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422 [TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300 [TBL] [Abstract][Full Text] [Related]
6. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM; Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963 [TBL] [Abstract][Full Text] [Related]
8. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901 [TBL] [Abstract][Full Text] [Related]
9. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009 [TBL] [Abstract][Full Text] [Related]
10. Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females. Subasinghe AK; Wark JD; Phillips S; Cornall A; Brotherton JML; Garland SM Sex Health; 2020 Dec; 17(6):510-516. PubMed ID: 33341122 [TBL] [Abstract][Full Text] [Related]
11. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study. McGregor S; Saulo D; Brotherton JML; Liu B; Phillips S; Skinner SR; Luey M; Oliver L; Stewart M; Tabrizi SN; Garland S; Kaldor JM Vaccine; 2018 Jul; 36(29):4311-4316. PubMed ID: 29880245 [TBL] [Abstract][Full Text] [Related]
12. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. Shilling H; Murray G; Brotherton JML; Hawkes D; Saville M; Sivertsen T; Chambers I; Roberts J; Farnsworth A; Garland SM; Hocking JS; Kaldor J; Guy R; Atchison S; Costa AM; Molano M; Machalek DA Vaccine; 2020 Jan; 38(5):1186-1193. PubMed ID: 31767467 [TBL] [Abstract][Full Text] [Related]
13. Partner-Level and Sexual Networking Factors Are Associated With Vaccine-Type and Nonvaccine-Type Human Papillomavirus Infection After Vaccine Introduction in Young Women. Kahn J; Washington C; Ding L; Wyllie T; Rosen B; Gorbach P Sex Transm Dis; 2022 Jun; 49(6):429-436. PubMed ID: 35093984 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017. Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001 [TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study. Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T Front Public Health; 2023; 11():1204101. PubMed ID: 37719724 [TBL] [Abstract][Full Text] [Related]
16. Anal Human Papillomavirus Prevalence Among Vaccinated and Unvaccinated Gay, Bisexual, and Other Men Who Have Sex With Men in Canada. Chambers C; Deeks SL; Sutradhar R; Cox J; de Pokomandy A; Grennan T; Hart TA; Lambert G; Moore DM; Coutlée F; Burchell AN; Sex Transm Dis; 2022 Feb; 49(2):123-132. PubMed ID: 34561370 [TBL] [Abstract][Full Text] [Related]
17. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. Purriños-Hermida MJ; Santiago-Pérez MI; Treviño M; Dopazo R; Cañizares A; Bonacho I; Trigo M; Fernández ME; Cid A; Gómez D; Ordóñez P; Coira A; Armada MJ; Porto M; Perez S; Malvar-Pintos A; PLoS One; 2018; 13(8):e0201653. PubMed ID: 30075010 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France. Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I; J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911 [TBL] [Abstract][Full Text] [Related]
19. Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018. Meites E; Winer RL; Newcomb ME; Gorbach PM; Querec TD; Rudd J; Collins T; Lin J; Moore J; Remble T; Swanson F; Franz J; Bolan RK; Golden MR; Mustanski B; Crosby RA; Unger ER; Markowitz LE J Infect Dis; 2020 Nov; 222(12):2052-2060. PubMed ID: 32504091 [TBL] [Abstract][Full Text] [Related]
20. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada. Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]